Management of luspatercept therapy in patients with transfusion-dependent β-thalassaemia. Review uri icon

Overview

abstract

  • Patients with transfusion-dependent β-thalassaemia require lifelong, regular red blood cell transfusions for survival; however, frequent blood transfusions are associated with an increased risk of iron overload, transfusion-transmitted disease and alloimmunization, as well as reduced quality of life. Luspatercept, an erythroid maturation agent that promotes late-stage erythroid maturation independently of erythropoietin, has demonstrated efficacy in reducing transfusion burden in patients with transfusion-dependent β-thalassaemia. In this review, we discuss treatment initiation, ongoing evaluation, dose adjustment and management of adverse events in transfusion-dependent patients with β-thalassaemia receiving luspatercept, and we provide guidance on how to determine whether patients are deriving clinical benefit.

publication date

  • April 10, 2023

Research

keywords

  • Iron Overload
  • beta-Thalassemia

Identity

Scopus Document Identifier

  • 85152639667

Digital Object Identifier (DOI)

  • 10.1111/bjh.18801

PubMed ID

  • 37037668

Additional Document Info

volume

  • 201

issue

  • 5